Spotlight on amisulpride in schizophrenia

CNS Drugs

Volumn 16, Issue 3, 2002, Pages 207-211

  Curran, Monique P ^a   Perry, Caroline M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; BENZAMIDE DERIVATIVE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; FLUPENTIXOL; HALOPERIDOL; PLACEBO; RISPERIDONE;

AGITATION; ANXIETY; CLINICAL TRIAL; DOPAMINERGIC TRANSMISSION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG TOLERABILITY; ENDOCRINE DISEASE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPERKINESIA; INSOMNIA; KIDNEY CLEARANCE; NEGATIVE SYNDROME; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SCHIZOPHRENIA; SOCIAL INTERACTION; WEIGHT GAIN;

EID: 0036214663     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200216030-00007     Document Type: Review

References (36)

1. 3 receptor antagonist with both presynaptic and limbic selectivity
2. Amisulpride: From animal pharmacology to therapeutic action
3. 3 dopamine receptor antagonist activity and limbic selectivity
4. Potentiation by low doses of selected neuroleptics of food-induced conditioned place preference in rats
5. Lack of interaction between amisulpride and lorazepam on psychomotor performance and memory in healthy volunteers
6. Psychomotor, cognitive, extrapyramidal, and affective functions of healthy volunteers during treatment with an atypical (amisulpride) and a classic (haloperidol) antipsychotic
7. Single oral doses of amisulpride do not enhance the effects of alcohol on the performance and memory of healthy subjects
8. Effects of haloperidol and amisulpride on motor and cognitive skill learning in healthy volunteers
9. The acute effects of amisulpride (50 mg and 200 mg) and haloperidol (2 mg) on cognitive function in healthy elderly volunteers
10. Effects of 50mg amisulpride on EEG, psychomotor and cognitive functions in healthy sleep-deprived subjects
11. Safety and pharmacokinetics of a single oral dose of amisulpride in healthy elderly volunteers
12. Safety of amisulpride (Solian): A review of 11 clinical studies
13. Effects of newer atypical antipsychotics on autonomic neurocardiac function: A comparison between amisulpride, olanzapine, sertindole, and clozapine
14. A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers
15. Pharmacokinetics and metabolism of amisulpride
16. Amisulpride pharmacokinetics: No difference between young and elderly subjects
17. Amisulpride: Kinetics in patients with renal failure
18. A comparative double-blind trial of amisulpride versus haloperidol in the treatment of acute psychotic disorders
19. A double blind, controlled, multicenter trial of amisulpride versus high dose haloperidol in acute psychotic disorders
20. Amisulpride, an atypical antipsychotic, in the treatment of acute episodes of schizophrenia: A dose-ranging study vs. haloperidol
21. Amisulpride versus haloperidol in treatment of schizophrenic patients: Results of a double-blind study
22. Improvement of acute exacerbations of schizophrenia with amisulpride: A comparison with haloperidol
23. 2-like antagonist
24. Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia
25. Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: Results of a multicentre, double-blind study
26. Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia
27. Amisulpride improves affective symptoms in acute schizophrenia
28. Clinical advantages of amisulpride in the treatment of acute schizophrenia
29. Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia
30. Treatment of negative symptoms in schizophrenia with amisulpride
31. Improvement of some schizophrenic deficit symptoms with low doses of amisulpride
32. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride
33. Amisulpride versus risperidone in schizophrenia: Comparing clinical and functional outcome in a 6 month study
34. One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms. Amisulpride vs. haloperidol
35. Economic assessment of neuroleptic strategies in schizophrenia